ECSP19020141A - Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino - Google Patents
Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalinoInfo
- Publication number
- ECSP19020141A ECSP19020141A ECSENADI201920141A ECDI201920141A ECSP19020141A EC SP19020141 A ECSP19020141 A EC SP19020141A EC SENADI201920141 A ECSENADI201920141 A EC SENADI201920141A EC DI201920141 A ECDI201920141 A EC DI201920141A EC SP19020141 A ECSP19020141 A EC SP19020141A
- Authority
- EC
- Ecuador
- Prior art keywords
- steroid
- disustituted
- pirazolyl
- crystaline
- formula
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- -1 19-nor-C21-C3,3-disubstituted pyrazolyl steroid Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Esta invención se refiere a un esteroide 19-nor-C21-pirazolilo C3,3-disustituido de la fórmula (I) y formas sólidas cristalinas y composiciones del mismo. También se describen en la presente métodos de preparación de formas sólidas cristalinas del esteroide 19-nor-C21-pirazolilo C3,3-disustituido de la fórmula (I) y métodos de uso del esteroide 19-nor-C21-pirazolilo C3,3-disustituido de la fórmula (I) o formas sólidas cristalinas, sales farmacéuticamente aceptables, y composiciones farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19020141A true ECSP19020141A (es) | 2019-04-30 |
Family
ID=59772778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201920141A ECSP19020141A (es) | 2016-08-23 | 2019-03-22 | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino |
Country Status (23)
Country | Link |
---|---|
US (3) | US11236121B2 (es) |
EP (2) | EP3981763A1 (es) |
JP (2) | JP2019524853A (es) |
KR (2) | KR20190040043A (es) |
CN (4) | CN115974954A (es) |
AR (3) | AR109393A1 (es) |
AU (3) | AU2017315682B2 (es) |
BR (1) | BR112019003637A2 (es) |
CA (1) | CA3034262A1 (es) |
CL (2) | CL2019000477A1 (es) |
CO (1) | CO2019002596A2 (es) |
EA (1) | EA201990565A1 (es) |
EC (1) | ECSP19020141A (es) |
IL (1) | IL302480A (es) |
JO (1) | JOP20190022B1 (es) |
MA (1) | MA46042A (es) |
MX (2) | MX2019002193A (es) |
PE (1) | PE20190915A1 (es) |
PH (1) | PH12019500375A1 (es) |
SG (1) | SG11201901445TA (es) |
TW (2) | TW202342059A (es) |
WO (1) | WO2018039378A1 (es) |
ZA (1) | ZA201901051B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2852057C (en) | 2011-10-14 | 2022-06-07 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
LT2986624T (lt) | 2013-04-17 | 2020-07-10 | Sage Therapeutics, Inc. | Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams |
AU2014290400B2 (en) | 2013-07-19 | 2019-12-05 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
KR102612943B1 (ko) | 2014-10-16 | 2023-12-13 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
EP4302764A2 (en) | 2016-07-11 | 2024-01-10 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
TW202342058A (zh) * | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
TW202339764A (zh) * | 2017-09-14 | 2023-10-16 | 美商賽吉醫療公司 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
US20210338692A1 (en) * | 2018-06-12 | 2021-11-04 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
US20230322846A9 (en) | 2018-12-05 | 2023-10-12 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
US20220098230A1 (en) * | 2019-01-31 | 2022-03-31 | Shenzhen Rentai Pharmatech Ltd. | y-AMINOBUTYRIC ACID MODULATOR CRYSTAL FORM X, PREPARATION METHOD AND APPLICATION THEREOF |
WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
KR20220066262A (ko) * | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
IL296645A (en) | 2020-03-25 | 2022-11-01 | Sage Therapeutics Inc | Use of substances to treat respiratory conditions |
US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
KR20230136599A (ko) | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
TW202300156A (zh) | 2021-03-17 | 2023-01-01 | 美商賽吉醫療公司 | 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇 |
AU2022267304A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
EP4329770A1 (en) | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
PE20240780A1 (es) | 2021-07-28 | 2024-04-17 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo |
WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
CA2396079A1 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
BR0307490A (pt) | 2002-02-08 | 2004-12-28 | Ono Pharmaceutical Co | Derivado de piperidina e composição farmacêutica que compreende o mesmo como ingrediente ativo |
US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
CA2892811A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
EP3753927B1 (en) * | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
KR102612943B1 (ko) | 2014-10-16 | 2023-12-13 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
EP3347368A4 (en) | 2015-09-08 | 2019-01-23 | Viewpoint Therapeutics, Inc. | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES |
JP2018530585A (ja) | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
CN109414444A (zh) | 2016-03-08 | 2019-03-01 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
EP4302764A2 (en) | 2016-07-11 | 2024-01-10 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
CN116370475A (zh) | 2017-08-31 | 2023-07-04 | 武田药品工业株式会社 | 中枢神经***病症的治疗 |
TW202342058A (zh) | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
TW202339764A (zh) | 2017-09-14 | 2023-10-16 | 美商賽吉醫療公司 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
SG11202004329TA (en) | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
KR20200104349A (ko) | 2017-12-22 | 2020-09-03 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
US20210101928A1 (en) | 2017-12-22 | 2021-04-08 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
WO2019140272A1 (en) | 2018-01-12 | 2019-07-18 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
US20210338692A1 (en) | 2018-06-12 | 2021-11-04 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
EP3864022B1 (en) | 2018-10-12 | 2023-09-20 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
US20210363175A1 (en) | 2018-10-19 | 2021-11-25 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
US20230322846A9 (en) | 2018-12-05 | 2023-10-12 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
BR112021012242A2 (pt) | 2018-12-21 | 2021-09-28 | Sage Therapeutics, Inc. | Esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida e composições destes |
TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
JP2023504517A (ja) | 2019-12-05 | 2023-02-03 | セージ セラピューティクス, インコーポレイテッド | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法 |
JP2023518411A (ja) | 2020-03-18 | 2023-05-01 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその使用方法 |
IL296645A (en) | 2020-03-25 | 2022-11-01 | Sage Therapeutics Inc | Use of substances to treat respiratory conditions |
US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2017
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Application Discontinuation
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es unknown
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko not_active Application Discontinuation
- 2017-08-23 TW TW112101437A patent/TW202342059A/zh unknown
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt active Search and Examination
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en active Application Filing
- 2017-08-23 MX MX2019002193A patent/MX2019002193A/es unknown
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US20230399357A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19020141A (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino | |
DOP2023000077A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
CO2018013497A2 (es) | Conjugados de anticuerpo y fármaco anti-egfr | |
CL2023000176A1 (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
BR112018072246A2 (pt) | síntese de indazóis | |
MX2018015280A (es) | Conjugados de anticuerpo y farmaco anti-egfr. | |
MX2018015284A (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
CL2020000217A1 (es) | Inhibidores de ror gamma. | |
CY1125355T1 (el) | Πεντακυκλικη ενωση | |
BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
JOP20190163B1 (ar) | منشط nrf2 | |
SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
DK3658553T3 (da) | Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf | |
MX2019010640A (es) | Formas cristalinas de acido obeticolico. | |
BR112018006969A2 (pt) | derivados de azetidina para formação de imagem de tau | |
UA120519U (uk) | Використання похідних 4-амінобутанової кислоти як антиамнестичних засобів | |
PL408052A1 (pl) | Nowa pochodna kwasu 5-amino-3-metylo-4-izoksazolokarboksylowego, sposób jej wytwarzania i zastosowanie |